Edgewise Therapeutics
Ying Qian has a comprehensive work experience spanning several positions in the field of research and scientific investigation.
Starting in 1988, Qian worked as a Lecturer at East China Normal University until 1993. Following this, Qian served as a Visiting Scientist at the University of Missouri at Columbia from 1993 to 1998.
In 1999, Qian joined the Neuroscience Center of the University of North Carolina at Chapel Hill as a Research Specialist, a position held until 2002.
From 2002 to 2015, Qian worked at GlaxoSmithKline as a Senior Scientist, contributing to pre-clinical small molecular and biologics drugs identification and validation. Additionally, Qian gained experience as a rat and mouse micro-surgeon, performing brain surgeries for genes and compounds specific delivery.
In 2015, Qian began working at Duke University as a Research Scientist (Microsurgeon), focusing on stem cell therapies for heart and muscle diseases. Qian conducted animal surgeries, such as coronary artery ligation, open chest heart surgeries, and skeletal muscle injury and repair surgeries.
Since April 2018, Qian has been associated with Edgewise Therapeutics, initially serving as a Senior Scientist before assuming the role of Research Investigator in August 2022.
Overall, Qian's work experience showcases a strong background in research investigation, micro-surgery, drug discovery, and stem cell therapies across different academic and industry settings.
Ying Qian obtained a Bachelor of Science (B.S.) degree in Physiology/Biology from East China Normal University from 1981 to 1985. Afterward, Ying pursued a Master of Science (M.S.) in Neuroscience at the Brain Function Institution at East China Normal University from 1985 to 1988. In terms of additional certifications, Ying obtained a certification in Rodent Microsurgery and Hemodynamic Measurement Program from the University of Wisconsin – Madison Cardiovascular Physiology and Surgery in October 2022. Prior to that, Ying received a Microsurgeon certification from the School of Medicine at Wake Forest University in 2010. Additionally, Ying holds a certification as a Rodent Brain and Vascular Surgeon from the School of Medicine at the University of North Carolina at Chapel Hill, earned in 2002.
This person is not in the org chart
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.